Is healthcare-associated pneumonia a distinct entity needing specific therapy?
Authors:
- Santiago EwigSESantiago Ewig
- Tobias WelteTWTobias Welte
- Antoni TorresATAntoni Torres
- 1 April 2012
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 25 (2) , 166-175
Abstract
Healthcare-associated pneumonia (HCAP) was introduced in 2005 by American Thoracic Society/Infectious Diseases Society of America guidelines as a new entity of pneumonia, resembling nosocomial pneumonia rather than community-acquired pneumonia (CAP) in terms of frequency of multidrug-resistant (MDR) pathogens and outcomes, thus requiring broad spectrum initial antimicrobial coverage in order to prevent inadequate treatment and, as a consequence, excess mortality. This concept continues to be a subject of controversy. Main concerns relate to the definition of HCAP, the true frequency of MDR pathogens, and the impact of MDR pathogens on outcomes. Definitions of HCAP and the relative frequencies of HCAP defining subgroups were highly variable. All studies demonstrated an increased severity of pneumonia at presentation and an excess mortality from HCAP as compared to CAP. The incidence of MDR pathogens in different observational studies was slightly increased but generally low in most studies originating from Europe, South Korea, Canada, and Japan. However, the data do not support a causal relationship of MDR incidence and excess mortality. Instead, after adjustment for confounders, mortality might be related to hidden or documented treatment restrictions in elderly and severely disabled patients. Accordingly, HCAP guideline concordant antimicrobial treatment did not improve outcomes. The HCAP concept is based on varying definitions poorly predictive of MDR pathogens. The incidence of MDR pathogens is far lower than supposed in the original guideline document, and MDR pathogens do not seem to be the main cause of excess mortality. Broad antimicrobial coverage does not alter outcomes. As the HCAP concept results in a tremendous overtreatment without any evidence for improved outcomes, it should not be implemented in clinical practice prior to clear evidence that it is superior to a careful assessment of individual risk factors for MDR pathogens.Keywords
This publication has 36 references indexed in Scilit:
- Clinical features of healthcare‐associated pneumonia (HCAP) in a Japanese community hospital: Comparisons among nursing home‐acquired pneumonia (NHAP), HCAP other than NHAP, and community‐acquired pneumoniaRespirology, 2011
- One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare SystemInternational Journal of Infectious Diseases, 2011
- Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospitalBMC Infectious Diseases, 2011
- Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumoniaCritical Care, 2011
- Role of multidrug-resistant pathogens in health-care-associated pneumoniaThe Lancet Infectious Diseases, 2011
- Clinical and Economic Outcomes for Patients with Health Care-Associated Staphylococcus aureus PneumoniaJournal of Clinical Microbiology, 2010
- Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumoniaInfection, 2010
- Rethinking the concepts of community-acquired and health-care-associated pneumoniaThe Lancet Infectious Diseases, 2010
- Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumoniaCurrent Opinion in Infectious Diseases, 2009
- Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center ExperienceAntimicrobial Agents and Chemotherapy, 2007